Similar articles for PMID: 30442756

Year	Number of Results
2010	1
2015	4
2016	20
2017	23
2018	29
2019	32
2020	26
2021	10
2022	3
2024	0

1

Early Experience of Rechallenge ¹⁷⁷Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer.

Gafita A, Rauscher I, Retz M, Knorr K, Heck M, Wester HJ, D'Alessandria C, Weber WA, Eiber M, Tauber R. Gafita A, et al. J Nucl Med. 2019 May;60(5):644-648. doi: 10.2967/jnumed.118.215715. Epub 2018 Nov 15. J Nucl Med. 2019. PMID: 30442756 Free article.

2

Outcome and safety of rechallenge [¹⁷⁷Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.

Yordanova A, Linden P, Hauser S, Meisenheimer M, Kürpig S, Feldmann G, Gaertner FC, Essler M, Ahmadzadehfar H. Yordanova A, et al. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1073-1080. doi: 10.1007/s00259-018-4222-x. Epub 2018 Nov 24. Eur J Nucl Med Mol Imaging. 2019. PMID: 30474706

3

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.

Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, Kumar AR, Akhurst T, Pattison DA, Beaulieu A, Mooi J, Tran B, Guo C, Kalff V, Murphy DG, Jackson P, Eu P, Scalzo M, Williams S, Hicks RJ, Hofman MS. Violet J, et al. J Nucl Med. 2020 Jun;61(6):857-865. doi: 10.2967/jnumed.119.236414. Epub 2019 Nov 15. J Nucl Med. 2020. PMID: 31732676 Free PMC article. Clinical Trial.

4

Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving ²²⁵Ac-PSMA-617 Radioligand Therapy.

Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, Davis C, Reyneke F, Maes A, Kratochwil C, Lengana T, Giesel FL, Van de Wiele C, Morgenstern A. Sathekge M, et al. J Nucl Med. 2020 Jan;61(1):62-69. doi: 10.2967/jnumed.119.229229. Epub 2019 May 17. J Nucl Med. 2020. PMID: 31101746 Free article.

5

Clinical Outcomes of ¹⁷⁷Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy.

Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Barber TW, et al. J Nucl Med. 2019 Jul;60(7):955-962. doi: 10.2967/jnumed.118.216820. Epub 2019 Jan 25. J Nucl Med. 2019. PMID: 30683770 Free article.

6

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ. Rahbar K, et al. J Nucl Med. 2017 Jan;58(1):85-90. doi: 10.2967/jnumed.116.183194. Epub 2016 Oct 20. J Nucl Med. 2017. PMID: 27765862 Free article.

7

²²⁵Ac-PSMA-617/¹⁷⁷Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience.

Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, Stemler T, Saar M, Bartholomä M, Ezziddin S. Khreish F, et al. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):721-728. doi: 10.1007/s00259-019-04612-0. Epub 2019 Nov 22. Eur J Nucl Med Mol Imaging. 2020. PMID: 31758224

8

Repeated ¹⁷⁷Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq.

Rathke H, Giesel FL, Flechsig P, Kopka K, Mier W, Hohenfellner M, Haberkorn U, Kratochwil C. Rathke H, et al. J Nucl Med. 2018 Mar;59(3):459-465. doi: 10.2967/jnumed.117.194209. Epub 2017 Aug 10. J Nucl Med. 2018. PMID: 28798031 Free article.

9

Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [¹⁷⁷Lu]Lu-PSMA-617.

Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Wei X, Schlenkhoff C, Hauser S, Essler M. Ahmadzadehfar H, et al. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1448-1454. doi: 10.1007/s00259-017-3716-2. Epub 2017 May 9. Eur J Nucl Med Mol Imaging. 2017. PMID: 28488028

10

Influence of short-term dexamethasone on the efficacy of ¹⁷⁷ Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Derlin T, Sommerlath Sohns JM, Schmuck S, Henkenberens C, von Klot CAJ, Ross TL, Bengel FM. Derlin T, et al. Prostate. 2020 May;80(8):619-631. doi: 10.1002/pros.23974. Epub 2020 Mar 18. Prostate. 2020. PMID: 32187729

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

117 results

Results by year